Welcome to the Annual General Meeting of Spermosens AB, reg. no. 559179-0380, on June 16, 2025, at 10:00 PM at Scheeletorget 1, Medicon Village, The Spark, Lund. Registration for the meeting begins at 09:30 PM.
Read more at CisionVälkommen till Spermosens AB:s, org. nr. 559179–0380, årsstämma den 16 juni 2025, kl. 10.00 på Scheeletorget 1, Medicon Village, The Spark, Lund. Inregistrering till stämman börjar kl. 09.30.
Read more at CisionWe have made solid progress during the first quarter, marked by positive interim results from our ongoing clinical study and the successful completion of financing to support our activities.
Read more at CisionSpermosens AB ("Spermosens" or the "Company") provides an update on its ongoing clinical study, commercial discussions and financing.
Read more at CisionSpermosens AB ("Spermosens" or the "Company") announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company´s patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team’s technology expertise is a key step in…
Read more at Cision
Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se
